Gastric Cancer
Conditions
Brief summary
This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.
Interventions
DIAGNOSTIC_TESTThe clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
Sponsors
Hunan Cancer Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Age over 18 years old; 2. Diagnosed as a patient with gastric cancer; 3. Receive FAPI PET/CT and FDG PET/CT imaging within one week; 4. Perform serum tumor marker testing one week before and after scanning
Exclusion criteria
1. History of other malignant tumors; 2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver; 3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination; 4. Patients with unorganized pathology or incomplete clinical data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 18F-FAPI-04 PET imaging diagnosis of gastric cancer detection rate | 2 years | Exploring the feasibility of using targeted fibroblast activation protein (FAP) PET/CT imaging for gastric cancer; Compare the advantages and disadvantages of 18F-FAPI-04 and 18F-FDG in gastric cancer imaging, explore the clinical application value of 18F-FAPI-04 PET/CT in gastric cancer imaging, and construct a molecular imaging diagnostic model for gastric cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detection rate of peritoneal metastasis in gastric cancer | 2 years | Comparison of the diagnostic value of 18F-FAPI-04 PET/CT and PET/MR for peritoneal metastasis of gastric cancer, and construction of a molecular imaging diagnostic model for peritoneal metastasis of gastric cancer |
Countries
China
Contacts
Primary ContactHui Ye
Outcome results
None listed